These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7828778)

  • 21. The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease.
    Jennings PE
    Adv Exp Med Biol; 1994; 366():313-24. PubMed ID: 7771262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
    Chan TK; Chan V; Teng CS; Yeung RT
    Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
    Chen LL; Yu F; Zeng TS; Liao YF; Li YM; Ding HC
    Eur J Pharmacol; 2011 Jun; 659(2-3):296-301. PubMed ID: 21453695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does gliclazide stimulate first-phase, second-phase, or both phases of insulin release?
    Cerasi E
    Horm Metab Res; 2002 Feb; 34(2):107-8; author reply 109-10. PubMed ID: 11972296
    [No Abstract]   [Full Text] [Related]  

  • 26. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
    Ligtenberg JJ; Reitsma WD; van Haeften TW
    Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
    Khanolkar MP; Morris RH; Thomas AW; Bolusani H; Roberts AW; Geen J; Jackson SK; Evans LM
    Atherosclerosis; 2008 Apr; 197(2):718-24. PubMed ID: 17765245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1990; ():325-34. PubMed ID: 2195215
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
    Lesobre B
    Sem Hop; 1983 Jun; 59(24):1827-33. PubMed ID: 6308816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function.
    Klaff LJ; Vinik AI; Jackson WP; Malan E; Kernoff L; Jacobs P
    S Afr Med J; 1979 Aug; 56(7):247-50. PubMed ID: 121645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium.
    Okouchi M; Okayama N; Omi H; Imaeda K; Fukutomi T; Nakamura A; Itoh M
    Diabetes Metab Res Rev; 2004; 20(3):232-8. PubMed ID: 15133755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of gliclazide beyond metabolic control.
    Ceriello A
    Metabolism; 2006 May; 55(5 Suppl 1):S10-5. PubMed ID: 16631804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide.
    Marquié G; Hadjiisky P; Arnaud O; Duhault J
    Am J Med; 1991 Jun; 90(6A):55S-61S. PubMed ID: 1872306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle.
    Rodríguez E; Pulido N; Romero R; Arrieta F; Panadero A; Rovira A
    Endocrinology; 2004 Feb; 145(2):679-85. PubMed ID: 14563700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K
    Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glycogen synthetase and non-insulin-dependent diabetes: role of gliclazide].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1991; ():315-21. PubMed ID: 1909395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.